iTeos Therapeutics | Sustainability Performance
Biotechnology company developing immuno-oncology therapies for cancer treatment.
2011
United States
51 - 200 employees
Biotechnology
$25M - 100M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#9448
Overall#2113
in United States#198
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Environmental
Nature and biodiversityClimate riskSocial
ExternalitiesGovernance
TargetsSDG ImpactESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projectionsAsset manager exclusion
Externalities
Critical
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Climate risk
OverallAcuteChronic
Reveal data for 20 credits
Unlock Acute & Chronic45Moderate
$5.5Bestimated revenue at risk
Thematic risk scoresESRS aligned scoresComing soon
Download Climate Risk AnalysisPowered by illuminem and GIST impactBiodiversity loss in km²
Reveal data for 2 credits
Biodiversity loss in terms of the equivalent land affected (km²e)
Total biodiversity loss (km²e)
Industry benchmark
Biodiversity loss in CO2e
Reveal data for 2 credits
Total biodiversity loss as CO2e tonnes
Total biodiversity loss (CO2e tonnes)
Industry benchmark
Powered by GIST and illuminem
Potential species loss
Reveal data for 2 credits
Estimated nature species lost due to corporate activity, expressed as Potentially Disappeared Fraction (PDF)
One row per year, with the latest at the top. Each driver uses its own scale.
Low ImpactHigh Impact
Industry benchmark
Biodiversity impact
Reveal data for 2 credits
| KPI | Metric | Year | |||||
|---|---|---|---|---|---|---|---|
| 2020 | 2021 | 2022 | 2023 | 2024 | Benchmark | ||
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | - | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | - | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | - | ******* | ******* | ******* | ******* | ******* |
PDF: Potentially Disappeared Fraction (of species) due to corporate activities
Land use
Reveal data for 2 credits
| KPI | Metric | Year | |||||
|---|---|---|---|---|---|---|---|
| 2020 | 2021 | 2022 | 2023 | 2024 | Benchmark | ||
| ******* | ******* | - | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | - | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | - | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | - | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | - | ******* | ******* | ******* | ******* | ******* |
Externalities
Reveal data for 1 credit
| KPI | Metric | Year | |||||
|---|---|---|---|---|---|---|---|
| 2020 | 2021 | 2022 | 2023 | 2024 | Benchmark | ||
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$35.0MFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Revenue by region
Revenue by region %
Gosselies, Belgium
United States
Powered by illuminem
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
R&D intensity
414.3%FY2024
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-23.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.3
▲ 2.7%
0.0
▼ 6.6%
0.0
▼ 25.1%
0.0
2030Powered by illuminem
Asset manager exclusions
Exclusions by region
Reveal data for 2 credits
Institutions excluding by region out of total tracked institutions
Excluding institutions
Reveal data for 2 credits
Institution name, type, screener label
Powered by illuminem and CovalenceEnvironmental policy coverage
Carbon reduction policy
Available
Human rights policy
Available
Recycling policy
Not available
Workplace health & safety policy
Available
0%
Independent Directors
0 out of 5 incl. management
Overall score
74
Environment
83
Social
99
Governance
41
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
SDG impact
Reveal data for 5 credits
Powered by illuminem and GIST Impact
SDG impact (historical)
Reveal data for 5 credits
| KPI | Metric | Year | |||||
|---|---|---|---|---|---|---|---|
| 2019 | 2020 | 2021 | 2022 | 2023 | Benchmark | ||
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
